CN1287808C - Ginkgo leaf extract composition - Google Patents
Ginkgo leaf extract composition Download PDFInfo
- Publication number
- CN1287808C CN1287808C CN 200410027882 CN200410027882A CN1287808C CN 1287808 C CN1287808 C CN 1287808C CN 200410027882 CN200410027882 CN 200410027882 CN 200410027882 A CN200410027882 A CN 200410027882A CN 1287808 C CN1287808 C CN 1287808C
- Authority
- CN
- China
- Prior art keywords
- buxine
- folium ginkgo
- ginkgo extract
- extract
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicinal composition of ginkgo biloba extract and buxine containing more than 24% of flavonoid and more than 6% of lactone classes. A weight proportion of buxine and ginkgo biloba extract is 1:1 to 1:80. The curative effect of the medicinal composition of ginkgo biloba extract and buxine provided by the present invention for treating cardio-cerebrovascular diseases is superior to any single formula. The present invention can be prepared into oral preparations, and is preferably prepared into dispersive tablets.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, be specifically related to contain the pharmaceutical composition of Folium Ginkgo extract and Buxine.
Background technology
Change has taken place in modern's dietary structure, and fat in the food and heat increase; The living condition is superior relatively, and physical exertion reduces.Some distinctive diseases are also following in the modern life, and the sickness rate of its center, cerebrovascular system disease rises year by year.Since the nineties, coronary heart disease, angina pectoris, arrhythmia have become common clinical, frequently-occurring disease from the last century.World Health Organization's prediction, to the year two thousand twenty, cardiovascular disease will be popular in developing country, wherein mainly be apoplexy and coronary heart disease.
In the medicine of treatment cardiovascular and cerebrovascular disease, Chinese medicine is because of its treating both the principal and secondary aspects of a disease, and toxic and side effects is little and receive publicity especially.Prove that through long-term clinical practice in the natural active matter of numerous treatment cardiovascular and cerebrovascular diseases, Buxine and Folium Ginkgo extract are that effect is good, well received medicine at present.These two kinds of natural active matters are successful embodiments that motherland's traditional medicine and modern pharmaceutical Technology organically combine.
Folium Ginkgo is China's special product Chinese crude drug, and aboundresources accounts for more than 70% of world's total amount.(Extracts of Ginkgo biloba EGB) has unique physiological and pharmacological effect and therapeutic value, and enjoys people to pay attention to Folium Ginkgo extract.Document thinks that the main pharmacological of Folium Ginkgo extract shows as: to central nervous system's effect, Antishock function, anti-allergic effects, to the protective effect of organ transplant rejection; except that above-mentioned effect; varying cyclically due to the immunoreation of pair cell, eyes pathological changes, the endotoxin all has inhibitory action, and reproductive system is also had effect.Existing ginkgo leaf extract oral preparation has preparations such as Folium Ginkgo tablet, soft capsule.
Mainly contain flavonoid and lactone in the Folium Ginkgo extract, flavonoid has antioxidation, has antiplatelet aggregative activity in the lactone, and Folium Ginkgo extract is to bring into play therapeutic effect by the comprehensive function of various different activities compositions.Now adopt separately usually and contain flavonoid more than 24%, the Folium Ginkgo extract of lactone more than 6% made pharmaceutical preparation.
A kind of alkaloid that Buxine system extracts from Buxaceae plant little leaf boxwood and congener thereof, molecular formula: C
26H
46N
20, also claim cyclovirobuxinum D.Experimentation and clinical observation through decades prove that this medical instrument resists myocardial ischemia, strengthens effects such as myocardial contraction, arrhythmia, protection acute cerebral ischemia.Be used for treatment of diseases such as coronary heart disease, angina pectoris, arrhythmia, myocardial infarction, cardiac insufficiency, high hypotension is had dual regulation, by blood brain barrier, microcirculation improvement is used for cerebral thrombosis, the cerebral oxygen supply deficiency.Have evident in efficacy, the characteristics that toxic and side effects is lower.The oral tablet of Buxine Tablet for making with Buxine recorded by the Pharmacopoeia of the People's Republic of China one one of version in 2000, and the contained Buxine of every tablet preparation in the Buxine Tablet in Buxine, should be the 90.0-110.0% of labelled amount, and its purity is quite high.Other dosage forms of Buxine have appearred in recent years; as injection; drop pill; the exploitation report and the patent documentation of slow releasing preparation etc.; but the exploitation of the compound preparation of Buxine is also fewer; as; application number is that 03112999.4 " compound recipe cyclovirobuxinum D tablet " is the compound recipe that HuanweihuangyangxingD and breviscapine are formed; the compound preparation that Folium Ginkgo extract and Buxine are not arranged; and flavonoid in the Folium Ginkgo extract and lactone active component and Buxine alkaloids active component; can produce the different activities composition; the synergistic therapeutic action of different mechanism of action, and can strengthen protective effect to cardio-cerebrovascular cell.
Summary of the invention
The object of the present invention is to provide the compound preparation of a kind of Folium Ginkgo extract and Buxine, the better efficacy of said preparation treatment cardiovascular and cerebrovascular disease.
Folium Ginkgo extract provided by the invention and Buxine pharmaceutical composition, it is characterized in that it is by containing flavonoid more than 24%, Folium Ginkgo extract and Buxine and the pharmaceutical excipient composition of lactone more than 6%, wherein, the ratio of the consumption of Buxine and Folium Ginkgo extract is: Buxine: Folium Ginkgo extract=1: 1 ~ 80.
Folium Ginkgo extract provided by the invention and Buxine pharmaceutical composition, the ratio of the consumption of Buxine and Folium Ginkgo extract is preferably: Buxine: Folium Ginkgo extract=1: 20 ~ 60.
Folium Ginkgo extract provided by the invention and Buxine pharmaceutical composition, the ratio of the consumption of Buxine and Folium Ginkgo extract be most preferably: Buxine: Folium Ginkgo extract=1: 40
Flavonoid in the Folium Ginkgo extract and lactone active component and Buxine alkaloids active component can produce the synergistic therapeutic action of different activities composition, different mechanism of action, and can strengthen the protective effect to cardio-cerebrovascular cell.The experiment proved that both compound recipes is all better than the curative effect of arbitrary single prescribed treatment cardiovascular and cerebrovascular disease, and this enlarges its clinical practice highly significant to improving curative effect.
Folium Ginkgo extract provided by the invention and Buxine pharmaceutical composition can be mixed with dispersible tablet, tablet, capsule, granule, preferred dispersible tablet, because dispersible tablet has been compared some advantage with conventional tablet: (1) taking convenience: Ke Huashui, also can work as conventional tablet and swallow, be convenient to the old people or the child takes; (2) absorb soon the bioavailability height; (3) be easy to carry, transport.During with Folium Ginkgo extract and Buxine preparation of pharmaceutical compositions medicament, the Folium Ginkgo extract and the Buxine that should comprise specified amount, and in medication preparation commonly used adjuvant, can comprise dispersant, surfactant, diluent, disintegrating agent, lubricant, binding agent as dispersible tablet as carrier.
The specific embodiment
Hereinafter the present invention is narrated in more detail, but scope of the present invention is not constituted any limitation by embodiment.
Embodiment 1:
Take by weighing 1 the gram Buxine and 2 the gram contain flavonoid more than 24%, the Folium Ginkgo extract mix homogeneously of lactone more than 6%, add then an amount of dispersant (as crospolyvinylpyrrolidone, polyvinylpyrrolidone, Macrogol 4000, polyethylene glycol 6000 etc.) grind solid dispersion, take by weighing other additive of tablet of recipe quantity and solid dispersion by the equivalent method mix homogeneously that progressively increases, add fluidizer and lubricant, mixing, tabletting is made about 1000 compound gingkgo blade.
Embodiment 2:
Take by weighing 1 the gram Buxine and 80 the gram contain flavonoid more than 24%, the Folium Ginkgo extract mix homogeneously of lactone more than 6%, add then an amount of dispersant (as crospolyvinylpyrrolidone, polyvinylpyrrolidone, Macrogol 4000, polyethylene glycol 6000 etc.) grind solid dispersion, take by weighing other additive of tablet of recipe quantity and solid dispersion by the equivalent method mix homogeneously that progressively increases, add suitable amount of adhesive system soft material, granulate, add and add disintegrating agent and lubricant, mixing, tabletting is made about 1000 compound gingkgo blade.
Embodiment 3:
Take by weighing 2 the gram Buxines and 80 the gram contain flavonoid more than 24%, the Folium Ginkgo extract mix homogeneously of lactone more than 6%, add then an amount of dispersant (as crospolyvinylpyrrolidone, polyvinylpyrrolidone, Macrogol 4000, polyethylene glycol 6000 etc.) grind solid dispersion, take by weighing other additive of tablet of recipe quantity and solid dispersion by the equivalent method mix homogeneously that progressively increases, dry granulation, granulate, add and add disintegrating agent and lubricant, mixing, tabletting is made about 1000 compound gingkgo blade.
Embodiment 4:
Take by weighing 5 the gram Buxines and 100 the gram contain flavonoid more than 24%, the Folium Ginkgo extract mix homogeneously of lactone more than 6%, add pharmaceutical excipient then (as carboxymethyl starch sodium, cross-linking sodium carboxymethyl cellulose, cellulose, polyvinylpolypyrrolidone etc.), the tablet method for making is made about 1000 compound gingkgo blade routinely.
Embodiment 5:
Ginkgo leaf extract composition is to mice normal pressure anoxia enduring and cerebral ischemia protective effect
Get 40 of Kunming mouses, body weight 20 ± 2g, the male and female dual-purpose, random packet, gastric infusion is put into the wide mouthed bottle that contains sodica calx behind the 6d, and vaseline sealing bottleneck is observed the mouse breathing dwell time.Other gets 70 of Kunming mouses, body weight 20 ± 2g, and the male and female dual-purpose, random packet, gastric infusion, continuous 6d, the 30min broken end is observed the mice time-to-live after the 6d administration.
Table 1 ginkgo leaf extract composition is to mice normal pressure anoxia enduring and cerebral ischemia protective effect (n=10)
| Group | Dosage mg/kg | The normal pressure anoxia enduring | The cerebral ischemia protection | ||
| Time-to-live (min) | Rate elongation (%) | Time-to-live (s) | Rate elongation (%) | ||
| The blank group | - | 18.17±2.53 | - | 10.25±2.24 | - |
| Buxine Folium Ginkgo extract ginkgo leaf extract composition (1: 40) | 2 80 82 | 21.42±1.53 22.85±2.45 25.78±2.37 **Δ | 17.9 25.8 41.9 | 11.88±2.10 13.11±1.60 14.02±1.53 *Δ | 15.9 18.1 36.8 |
*Compare with the Folium Ginkgo extract group, P＜0.05,
*Compare P＜0.01 with the Folium Ginkgo extract group
ΔCompare P＜0.01 with the Buxine group
The ginkgo leaf extract composition group compares with the Buxine group the protective effect of mice normal pressure anoxia enduring, and P＜0.01, the equal significance of difference are compared with the Folium Ginkgo extract group in P＜0.01; Ginkgo leaf extract composition compares with the Buxine group the protective effect of mouse brain ischemia, and P＜0.05, difference significance are compared with the Folium Ginkgo extract group in P＜0.01.
By this experiment as seen, ginkgo leaf extract composition obviously is better than independent use Buxine or Folium Ginkgo extract group to mice normal pressure anoxia enduring and cerebral ischemia protective effect.
Embodiment 6:
Ginkgo leaf extract composition is to the protective effect of acute myocardial ischemia
Get 16 of healthy dogs, be divided into 4 groups at random.Behind the gastric infusion 6d, intravenous anesthesia, tracheal intubation connects respirator, opens breast, makees the pericardium bed, separates ramus descendens anterior arteriae coronariae sinistrae, and its nearly 1/2 place is as the ligation position.Behind the coronary ligation 4 hours, inject burnt black ink through left auricle to left atrium, take off heart rapidly, remove atrium and right ventricle's flesh, freezing weighing, parallel coronary sulcus is cut into 5 of uniform thickness with cardiac muscle under coronary ligation point, weighs respectively, calculate non-ischemic region (dyeing) and ischemic region (not dyeing) with planimeter, calculate the percentage rate that ischemic region accounts for left ventricular mass.Then, 5 cardiac muscles are put in the N-BT liquid dye, as above obtain the percentage rate that infarct (light yellow) accounts for the myocardium weight of ischemic region (skipper).
Table 2 ginkgo leaf extract composition is to the protective effect (n=4) of acute myocardial ischemia
| Grouping | The ischemic region heart heavy * 100% | The infarct heart heavy * 100% |
| The left ventricle heart is heavy | The ischemic region heart is heavy | |
| The combination of blank group Buxine group 2mg/kg Folium Ginkgo extract group 80mg/kg Folium Ginkgo extract | 18.17±10.53 15.56±5.25 13.67±5.87 10.54±7.75 *Δ | 86.12±5.89 72.54±12.45 65.57±15.63 54.21±8.68 *Δ |
| Thing (1: 40) | 82mg/kg |
*Compare P＜0.05 with the Folium Ginkgo extract group
ΔCompare P＜0.01 with the Buxine group
Ginkgo leaf extract composition can improve blood supply of cardiac muscle, compares with the Buxine group, and P＜0.05, difference significance are compared with the Folium Ginkgo extract group in P＜0.01; Ginkgo leaf extract composition improves the effect of myocardial infarction, compares with the Buxine group, and P＜0.05, difference significance are compared with the Folium Ginkgo extract group in P＜0.01.
Buxine and Folium Ginkgo extract compound recipe sheet can improve the degree of myocardial ischemia preferably, improve blood supply of cardiac muscle, reduce myocardial infarct size, and effect obviously is better than using separately Buxine or Folium Ginkgo extract group.
Claims (6)
1, a kind of pharmaceutical composition that is used for the treatment of cardiovascular disease that contains Folium Ginkgo extract and Buxine, it is characterized in that it is by containing flavonoid more than 24%, Folium Ginkgo extract and Buxine and the pharmaceutical excipient composition of lactone more than 6%, wherein, the ratio of the consumption of Buxine and Folium Ginkgo extract is: Buxine: Folium Ginkgo extract=1: 1 ∽ 80.
2, the pharmaceutical composition that is used for the treatment of cardiovascular disease according to claim 1, Buxine and contain flavonoid more than 24%, the ratio of the consumption of the Folium Ginkgo extract of interior enzyme more than 6% is: Buxine: Folium Ginkgo extract=1: 20 ∽ 60.
3, the pharmaceutical composition that is used for the treatment of cardiovascular disease according to claim 2, Buxine and contain flavonoid more than 24%, the ratio of the consumption of the Folium Ginkgo extract of interior enzyme more than 6% is: Buxine: Folium Ginkgo extract=1: 40.
4, the pharmaceutical composition that is used for the treatment of cardiovascular disease according to claim 1, it is used to be mixed with peroral dosage form.
5, the pharmaceutical composition that is used for the treatment of cardiovascular disease according to claim 4, it is used to be mixed with tablet, capsule, granule.
6, the pharmaceutical composition that is used for the treatment of cardiovascular disease according to claim 5, it is used to be mixed with dispersible tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410027882 CN1287808C (en) | 2004-07-05 | 2004-07-05 | Ginkgo leaf extract composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410027882 CN1287808C (en) | 2004-07-05 | 2004-07-05 | Ginkgo leaf extract composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1593562A CN1593562A (en) | 2005-03-16 |
| CN1287808C true CN1287808C (en) | 2006-12-06 |
Family
ID=34664063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410027882 Active CN1287808C (en) | 2004-07-05 | 2004-07-05 | Ginkgo leaf extract composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1287808C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105495153B (en) * | 2014-10-16 | 2018-08-10 | 深圳海王药业有限公司 | A kind of antioxidant health-care product containing phycocyanin and ginkgo biloba p.e |
| CN106668099A (en) * | 2016-12-27 | 2017-05-17 | 江苏千药堂国医研究院有限公司 | Composition containing ginkgo leaf extract-PVP coprecipitate |
| CN109078002A (en) * | 2018-09-23 | 2018-12-25 | 吉林省中医药科学院（吉林省中医药科学院第临床医院） | Cyclovimbuxine D solid dispersions preparation method and its new medical use |
| CN110897056B (en) * | 2019-12-30 | 2023-08-25 | 内江师范学院 | Ginkgo leaf extract fish feed adhesive and preparation method and application thereof |
-
2004
- 2004-07-05 CN CN 200410027882 patent/CN1287808C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN1593562A (en) | 2005-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101890040B (en) | Composition with anti-fatigue effect and application thereof | |
| CN1181237A (en) | Solid pharmaceutical preparation | |
| KR101493016B1 (en) | A new use of traditional chinese medical composition | |
| CA2664935A1 (en) | Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c | |
| CN102008481A (en) | Eprosartan-containing compound preparation for treating hypertension | |
| CN1943618A (en) | Red sage root effective part standard extract and its preparing method and use | |
| CN111840112B (en) | Application of carnosic acid or derivatives thereof in preparing medicine for treating diabetic complications | |
| CN1287808C (en) | Ginkgo leaf extract composition | |
| CN102008491A (en) | Fosinopril-containing compound preparation for treating hypertension | |
| CN107007614A (en) | The medical usage of cycloastragenol | |
| CN100471500C (en) | Medicinal composition contg. glucoside of pueravia flower and its application | |
| CN1686423A (en) | Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method | |
| RU2408383C1 (en) | Composition with antineoplastic and adaptogenic activity (versions) and based drug (versions) | |
| CN101564394B (en) | Pharmaceutical composition containing ivabradine and trimetazidine | |
| CN113633657A (en) | Pharmaceutical composition for improving anti-fatigue, anti-hypoxia, heat-resistant and cold-resistant abilities of organism and application thereof | |
| CN1494902A (en) | Application of high-solubility berberine in preparation of medicine. | |
| CN107951940B (en) | Blood pressure lowering medicine composition | |
| US5077294A (en) | Products containing verapamil or gallopamil and prazosin | |
| CN1299676C (en) | Anti-anoxia medicinal composition | |
| CN101444523B (en) | Application of pueraria flower glucoside in preparation of medical compound for remedying osteoporosis | |
| CN1686242A (en) | Composition possessing therapeutic effect for high blood fat and heart brain blood vessel diseases | |
| CN1172702C (en) | Sugar-free erigeron breviscapus granule and its prepn and application | |
| CN102283832B (en) | Medicinal composition for preventing or treating hypertensive obese patient and application thereof | |
| CN1481796A (en) | Medication for adiposity | |
| CN1395933A (en) | Medicine for treating cardiovascular and cerebrovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhang Lijuan |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhang Lijuan Document name: patent for invention |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhang Shaojun Document name: Notice of conformity |